Page 6 - ANTIFUNGAL SUSCEPTIBILITY OF CLINICAL YEAST ISOLATES 2018-2020

Executive summary

This report summarizes antifungal susceptibility surveillance data for

yeasts isolated from clinical samples for the years 2018 to 2020. The data presents
the incidence of common Candida infections against major antifungals used in

treatment of candida infections.

The incidence of Candidaemia (all Candida species isolated from blood) was

3.08 per 100,000 population (number of blood isolates: 1,019) in 2018 -2020,

accounting 0.003%. The most common type of Candida species isolated from all
samples was Candida tropicalis in 2018 and 2019; whereas Candida albicans in

2020. C.albicans, C.tropicalis, C.glabrata complex and C.parapsilosis complex

remain the most common types of Candida recovered from the clinical samples.

A total of 1039 isolates (277 isolates in 2018, 475 isolates in 2019 and 287

isolates in 2020) were analyzed based on the first isolate per patient among thirty-
nine (39) hospitals and one (1) institution. The analysis was performed using the

WHONET 2019 software. The minimum inhibitory concentration (MIC) values

were determined by using the E-test method, Sensititre YeastOne TM or Vitek 2
System. The Clinical breakpoints (CBPs) and Epidemiological Cut-Off values

(ECV) are based on MICs outlined by the CLSI Performance Standards for

Antifungal Susceptibility Testing of Yeasts (M60, 2 edition and M59, 3 edition).
nd
rd
These were used to interpret whether isolates were susceptible, intermediately
susceptible, susceptible-dose-dependent or resistance to the tested antifungals.

When the interpretation zones were unavailable in the CLSI, the ECV

breakpoints were used.

The anti-fungal susceptibility testing showed that Candida albicans

susceptibility to echinocandins is 96% for anidulafungin, 94% for micafungin, and
66.2% for caspofungin, 92.9% is susceptible to fluconazole and 88.1% to

voriconazole.

6 |